Barclays Maintains an 'Overweight' on Watson Pharmaceuticals (WPI); Waiting for Lidoderm Ends

Go back to Barclays Maintains an 'Overweight' on Watson Pharmaceuticals (WPI); Waiting for Lidoderm Ends